In view of the encouraging results of immunomodulatory mAb in clinic for treatment of multiple solid tumor [54], our finding that PD-1 blockade and OX40 activation synergistically induce a potent antitumor effect in a highly clinical relevant ID8 ovarian cancer model should aid the design of future trials for ovarian cancer immunotherapy. Here, TNFRSF4 is linked to ovarian cancer.